Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-03
2009-02-03
Shiao, Rei-tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S492000, C548S361100
Reexamination Certificate
active
07485659
ABSTRACT:
Compositions, containing a ruthenium(III) complex and a heterocycle, methods for their manufacture, medicament containing these compositions and a kit.The invention relates to a composition (A), obtained by reacting a compound of the general formula (I)in-line-formulae description="In-line Formulae" end="lead"?M3−n−p−2pr[RUX6−n−p−q−2rBn(H2O)p(OH)q(O)r]2r+1 (I)in-line-formulae description="In-line Formulae" end="tail"?with a compound of the general formula (II)in-line-formulae description="In-line Formulae" end="lead"?B′(HX′)s (II).in-line-formulae description="In-line Formulae" end="tail"?Furthermore, the invention relates to a composition (B), obtained by mixing a compound of the general formula (III)in-line-formulae description="In-line Formulae" end="lead"?(B′H)3−n−p−2pr[RUX6−n−p−q−2rBn(H2O)p(OH)q(O)r]2r+1 (III)in-line-formulae description="In-line Formulae" end="tail"?with a compound of the general formula (IV)in-line-formulae description="In-line Formulae" end="lead"?MX′ (IV).in-line-formulae description="In-line Formulae" end="tail"?
REFERENCES:
patent: 4843069 (1989-06-01), Keller et al.
patent: WO 97/36595 (1997-10-01), None
F.T. Garson et al., “Comparative antitumor activity of ruthenium derivatives with 5′-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats,”Cancer Chemother Pharmacol, pp. 347-349 (1987).
B.K. Keppler et al., “New Ruthenium Complexes for the Treatment of Cancer,”Progress in Clinical Biochemistry and Medicine, vol. 10, pp. 41-69 (1989).
H. Depenbrock et al., “Preclinical Activity of Trans-indazolium [Tetrachlorobisindazoleruthenate (III)] (NSC 666158; IndCR; KP 1019) Againt Tumour Colony-forming Units and Haematopoietic Progenitor Cells,”European Journal of Cancer, vol. 33, No. 14, pp. 2404-2410 (1997).
A. Galeano et al., “Antitumor Activity of Some Ruthenium Derivatives in Human Colon Cancer Cell Lines in vitro,”Arzneim.-Forsch./Drug Res., 42, vol. 1, No. 6, pp. 821-824 (1992).
F. Kratz et al., “Protein-Binding Properties Of Two Antitumour Ru(III) Complexes To Human Apotransferring And Apolctoferrin,”Metal-Based Drugs, vol. 1, Nos. 2-3, pp. 169-173 (1994).
F. Kratz et al., “Comparison Of The Antiproliferative Activity Of Two Antitumour Ruthenium(III) Complexes With Their Apotransferrin and Transferrin-Bound Forms in a Human Colon Cancer Cell Line,”Metal-Based Drugs, vol. 3, No. 11, pp. 15-23 (1996).
Y.N. Vashisht Gopal et al., “Topoisomerase II poisoning by indazole and imidazole complexes of ruthenium,”J. Biosci, vol. 26, No. 2, pp. 271-276 (2001).
Ernst D. Kreuser et al., “Synergistic Antitumor Interactions Between Newly Synthesized Ruthenium Complexes and Cytokines in Human Colon Carcinoma Cell Lines,”Seminars in Oncology, vol. 19, No. 2 Suppl 3, pp. 73-81 (1992).
S. Pacor et al., “Antitumor action of mer-trichlorobis (dimethylsulphoxide) aminoruthenium (III) (BBR2382) in mice bearing lewis lung carcinoma,”Metal Ions in Biology and Medicine, pp. 482-484 (1990).
F. Kralik et al., “Complex compounds of trivalent ruthenium with pyrazol and imidazol,”Collection Czechoslov. Chem. Commun., vol. 26, pp. 1298-1304 (1961).
B.K. Keppler et al., “Synthesis Molecular Structure, and Tumor-Inhibiting Properties of Imidazolium trans-Bis(imidazole) tetrachlororuthenate(III) and its Methyl-Substituted Derivatives,”Inorg. Chem., vol. 26, pp. 4366-4370 (1987).
Martin R. Berger et al., “Efficacy of New Ruthenium Complexes against Chemically Induced Autochthonous Colorectal Carcinoma in Rats,”Anticancer Res., vol. 9, pp. 761-766, (1989).
E. Alessio et al., “Carbonyl Derivatives of Chloride-Dimethyl Sulfoxide-Ruthenium(II) Complexes: Systhesis, Structural Characterization, and Reactivty of Ru(CO)x(DMSO)4-xC12Complexes (x=1—3),”Inorg. Chem., vol. 34, pp. 4722-4734. (1995).
Woflgang Peti et al., “Synthesis of Tumor-Inhibiting Complex Salts Containing the Anion trans-Tetrachlorobis(indazole)ruthenate(III) and Crystal Structure of the Tetraphenhylphosphonium Salt,”Eur. J. Inorg. Chem., pp. 1551-1555, (1999).
B.K. Keppler et al., “New Tumor-Inhibiting Metal Complexes, Chemistry and Antitumor Properties,”Met-Based Drugs, vol. 1, Nos. 2-3, pp. 145-150, (1994).
Matthias H. Seelig et al., “Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats,”J. Cancer Res. Clin. Oncol., vol. 118, No. 3, pp. 195-200 (1992).
Michael J. Clark, “The Potential of Ruthenium in Anticancer Pharmaceuticals,”American Chemical Society Symp. Ser., pp. 157-180 (1980).
Keller et al., European Journal of Inorganic Chemistry (1999), (9), 1551-1555.
Djinovic, V., et al., “Novel ruthenium complex K2[Ru(dmgly)C14].2H2O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes,” J. Inorg. Biochem., 98(12):2168-73 (Dec. 2004) (Abstract Only).
Van Rensburg, C.E., et al., “Cytotoxicity of a series of water-soluble mixed valent diruthenium tetracarboxylates,” Anticancer Res., 22(2A):889-92 (Mar.-Apr. 2002) (Abstract Only).
Heffeter, P., et al., “Intrinsic and Acquired Forms of Resistance against the Anticancer ruthenium Compound KP1019 [Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A),” The Journal of Pharmacology and Experimental Therapeutics, 312(1):281-289 (2005).
Gaiddon, C., et al., “Ruthenium (II)-Derived Organometallic Compounds Induce Cytostatic and Cytotoxic Effects on Mammalian Cancer Cell Lines through p53-Dependent and p53-Independent Mechanisms,” The Journal of Pharmacology and Experimental Therapeutics, 315(3):1403-1411 (2005).
Faustus Forschungs CIE, Translational Cancer Research GmbH
Perkins Coie LLP
Shiao Rei-tsang
Zhu James
LandOfFree
Anticancer compositions, and methods of making and using the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anticancer compositions, and methods of making and using the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anticancer compositions, and methods of making and using the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4069662